stockportfolio.pro
COO vs GMAB: Which Stock Is the Better Buy?
The Cooper Companies, Inc. and Genmab A/S side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — COO vs GMAB, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| The Cooper Companies, Inc. (COO) | Genmab A/S (GMAB) | |
|---|---|---|
| Market cap | $14.5B | $15.3B |
| Revenue (latest FY) | $4.09B | $3.72B |
| Net income (latest FY) | $374.90M | $963.00M |
| Revenue growth (5y CAGR) | 11.0% | 21.2% |
| Net margin | 9.2% | 25.9% |
| Return on equity | 4.6% | 16.5% |
| P/E ratio | 62.9 | 19.1 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 4 |
| Positive free cash flow | Yes | Yes |
See the full COO vs GMAB breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open COO's full financials → Open GMAB's full financials →More comparisons
Frequently asked questions
Which is bigger, COO or GMAB?
Genmab A/S is larger by market capitalization — $15.3B versus $14.5B.
Which grows faster, COO or GMAB?
Over the last five fiscal years, Genmab A/S grew revenue faster — 21.2%/yr versus 11.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.